◼ Archived
Business
Enveda Raises $311 Million From Leading AI and Biotech Investors to Bring Pharma Into the 21st Century
Enveda secures $311 million in venture funding to advance nature-derived AI drugs into clinical trials.
Biopharma Dive
8 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
🔮 fades ✓
Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes
Takeda Pharmaceutical's R&D chief Andy Plump is set to retire in June 2027 following a period of significant pipeline reorganization and regulatory success.
◼ Archived
Business
🔮 fades ✗
Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial
Novartis and Ionis face setbacks as a high-stakes Phase 3 trial for an Lp(a) cardiovascular drug fails to meet its primary goals.
◼ Archived
Business
🔮 fades ✗
Regenxbio gene therapy refiling plan derailed by FDA hold over spine MRI findings
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Eli Lilly is suing six companies over illegal sales of its unapproved weight loss drug
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✗
Why Sionna Therapeutics Stock Is Crashing 91% to a Record Low
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✗
The Race to Come Up With the Next Big Sleep Drug
Takeda's historic narcolepsy approval ignites a wave of new pharmaceutical development in the sleep drug market.